New avenues for second-line treatment of metastatic non-small-cell lung cancer

References

• Parkin DM, Bray F, Ferlay J et al. Global statistics cancer, 2002. CA Cancer J. Clin.55, 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Ries LAG, Eisner MP, Kosary CL et al.SEER Cancer Statistics Review, 1975–2001. National Cancer Institute, MD, USA (2004).
   Google Scholar
• Sant M, Aareleid T, Berrino F et al. EUROCARE-3; survival of cancer patients diagnosed 1990–94 – results and commentary. Ann. Oncol.14(Suppl. 5), v61–v118 (2003).
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ311, 899–909 (1995).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. New. Engl. J. Med.355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Manegold C, von Pawel J, Zatloukal P et al. Randomised, double-blind multicentre Phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J. Clin. Oncol.25(18 Suppl.), LBA7514 (2007).
   Google Scholar
• Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J. Clin. Oncol.18, 3722–3730 (2000).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 . J. Clin. Oncol.22, 330–353 (2003).
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Bepler G, Bueno R et al. Non-small cell lung cancer clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw.4, 548–582 (2006).
   PubMedGoogle Scholar
• Hotta K, Fujiwara Y, Kiura K et al. Relationship between response and survival in more than 50000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 Phase III trials. J. Thorac. Oncol.2, 402–407 (2007).
   PubMed Web of Science ®Google Scholar
• Bonomi P, Langer C, O’Brien M et al. Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized Phase III trial comparing docetaxel and paclitaxel poliglumex (PPX). J. Clin. Oncol.24(18 Suppl.), S374 (2006).
   Google Scholar
• Weiss GJ, Rosell R, Fossella F et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann. Oncol.18, 453–460 (2007).
   PubMed Web of Science ®Google Scholar
• Murillo JR, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small-cell lung cancer. Oncologist11, 1095–1099 (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18, 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol.18, 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously based with platinum-based chemotherapy: results of a prospective, randomized Phase III trial. Lung Cancer43, 183–194 (2004).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA 3rd, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol.16, 2164–2168 (1998).
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer92, 2158–2163 (2001).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Di Maio M et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3-week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br. J. Cancer91, 1996–2004 (2004).
   PubMed Web of Science ®Google Scholar
• Gervais R, Ducolone A, Breton JL et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann. Oncol.16, 90–96 (2005).
   PubMed Web of Science ®Google Scholar
• Schuette W, Nagel S, Blankenburg T et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J. Clin. Oncol.23, 8389–8395 (2005).
   PubMed Web of Science ®Google Scholar
• Camps C, Massuti B, Jimenez A et al. Randomized Phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann. Oncol.17, 467–472 (2006).
   PubMed Web of Science ®Google Scholar
• Lai CL, Tsai CM, Chiu CH. Phase II randomized trial of tri-weekly versus day 1 and 8-weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn. J. Clin. Oncol.35, 700–706 (2005).
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F, Chiodini P et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol.25, 1377–1382 (2007).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer. J. Clin. Oncol.26(21), 3543–3551 (2008).
   PubMed Web of Science ®Google Scholar
• Peterson P, Park K, Fossella F. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2–6 September 2007.
   Google Scholar
• Ramlau R, Gervais R, Krzakowski M et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J. Clin. Oncol.24, 2800–2807 (2006).
   PubMed Web of Science ®Google Scholar
• Krzakowski M, Douillard J, Ramlau R et al. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen. J. Clin. Oncol.25(18S), 7511 (2007).
   Web of Science ®Google Scholar
• Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized Phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol.24, 4405–4411 (2006).
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Bernardini I, Chella A et al. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin. Lung Cancer6, 401–405 (2006).
   Google Scholar
• Ciardiello F, De Vita F, Orditura M et al. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr. Opin. Oncol.16, 130–135 (2004).
   Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353, 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Clark GM, Zborowski D, Santabárbara P et al. Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression. J. Clin. Oncol.23(16 Suppl.), S374 (2005).
   Google Scholar
• Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.24, 3831–3837 (2007).
   Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366, 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Kim E, Hirsh V et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pretreated with platinum-based chemotherapy: a randomized open-label Phase III study (INTEREST): PRS-02. J. Thorac. Oncol.2(Suppl. 4), S305–S306 (2007).
   Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82, 4–6 (1990).
   PubMed Web of Science ®Google Scholar
• Keshet E, Ben-Sasson SA. Anticancer drug targets: approaching angiogenesis. J. Clin. Invest.104, 1497–1501 (1999).
   PubMed Web of Science ®Google Scholar
• Maione P, Gridelli C, Troiani T et al. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist11, 274–284 (2006).
   PubMed Web of Science ®Google Scholar
• Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res.62, 2554–2560 (2002).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res.9, 1546–1556 (2003).
   PubMed Web of Science ®Google Scholar
• Herbst RS, O’Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol.25, 4743–4750 (2007).
   PubMed Web of Science ®Google Scholar
• Natale RB, Bodkin D, Govindan R et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized Phase II trial. J. Clin. Oncol.24(18 Suppl.), 364s (2006).
   Google Scholar
• Heymach JV, Johnson BE, Prager D et al. Vandetanib (ZD6474) plus docetaxel in patients with previously treated non-small cell lung cancer: results of a randomized, placebo-controlled Phase I/II study. J. Clin. Oncol.25, 4270–4277 (2007).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.Blood101, 3597–3605 (2003).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer. Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Socinski MA, Novello S, Brahmer JR et al. Multicenter, Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol.26, 650–656 (2008).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang LY et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2005).
   Web of Science ®Google Scholar
• Schiller JH, Lee JW, Hanna NH et al. A randomized discontinuation Phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 8014).
   Google Scholar
• Gutierrez M, Kummar S, Allen D et al. A Phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC). J. Clin. Oncol.26(Suppl.) (2008) (Abstract 19084).
   Google Scholar
• Pirker R, Szczesna A, von Pawel J et al. FLEX: a randomized, multicenter, Phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer. J. Clin. Oncol.26(18 Suppl.), S1006 (2008).
   Google Scholar
• Kim ES, Mauer AM, Tran HT et al. A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc. Am. Soc. Clin. Oncol.22, 642 (2003).
   Google Scholar
• Jalal SI, Waterhouse D, Edelman M et al. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a Phase I–IIa dose-ranging study from the Hoosier Oncology Group. J. Clin. Oncol.25(18 Suppl.), 7698 (2007).
   Google Scholar
• Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol.24, 5253–5258 (2006).
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist13, 28–36 (2008).
   PubMedGoogle Scholar
• Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.26, 4268–4275 (2000).
   Google Scholar
• Cervantes T. Macarulla, E. Martinelli et al. Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol.26(Suppl.) (2008) (Abstract 4129).
   Google Scholar
• Mita AC, Sweeney CJ, Baker SD et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J. Clin. Oncol.24, 552–562 (2006).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Galetta D et al. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. J. Thorac. Oncol.2, 96–98 (2007).
   Google Scholar